Laboratory course of patient 002. Because of renal insufficiency, patient 002 was treated with erythropoietin 5000 IU 3 times per week in addition to sutimlimab. This increased the speed with which her hemoglobin rose when compared with the phase 1 trial. She received 10 infusions of sutimlimab 60 mg/kg (4.5 g) over the course of 5 months. Her hemoglobin increased from 7.9 to 9.0 g/dL within 1 week and reached 13.4 g/dL after 9 weeks. Her participation in the NPP was terminated because of the diagnosis of a massive inoperable uterine cancer with unilateral hydronephrosis which required radiotherapy. After exclusion from the NPP, the patient received regular transfusions every 1 to 2 weeks. As part of a different study, the patient began treatment with rituximab 2 weeks before the last administered dose of sutimlimab. Although CD20⁺ cells decreased immediately and remained low over the course of treatment, she was not able to achieve an adequate clinical response. Approximately 1 year later, the patient developed sepsis after a stroke and subsequently died.